Beta Bionics (NASDAQ:BBNX) executives used a conference presentation to outline the company’s strategy in insulin delivery, emphasizing automation, pharmacy reimbursement, and an expanding commercial footprint as key pillars of its growth plan.
Positioning iLet around “automation-forward” insulin delivery
Chief Financial Officer Stephen Feider described Beta Bionics’ iLet insulin pump as differentiated primarily by its approach to automation. He said patients can start the system by entering body weight and selecting “Go,” after which the pump’s learning algorithm adapts and delivers insulin. Patients are intended to announce meals, but Feider noted many do not, and he argued iLet is designed to accommodate varying levels of engagement.
What Beta says it takes to “win” in insulin pumping
In discussing competition, Feider framed long-term success around what he believes patients and clinicians ultimately want from insulin pump therapy. He outlined several requirements, emphasizing that patients should be able to engage with the system if they choose—but not be required to do so—and that automation should be strong enough to support that flexibility.
He also highlighted factors beyond algorithms, including form factor, continuous glucose monitor (CGM) choice, and reimbursement channel. Feider argued that broad market leadership requires offering both tubed and patch pump options, integrating with the CGMs patients prefer, and enabling pharmacy-channel purchasing. He described insulin pump adoption as still “way under-penetrated,” suggesting room for market expansion.
New patient share and who is adopting iLet
Feider said the company exited 2025 with roughly 10% new patient market share, and he described two primary cohorts driving adoption:
- Early adopters who want a highly automated experience.
- Patients who “would not do well” on other pumps due to the level of engagement required.
As evidence of the second cohort, Feider said the average A1C among patients starting on iLet is about 9, indicating many begin with relatively high baseline glucose levels. He also said about 70% of iLet patients come from injections rather than switching from other pumps, which he characterized as market expansion.
Addressing a perception that iLet is primarily a niche product for hard-to-manage patients, Feider said he disagreed and positioned iLet as broadly applicable. He argued the system can deliver outcomes that are “as good or better” with less work for both patients and providers, including for those already achieving good control on other systems but with higher effort.
Barriers to adoption: patch preference, control preference, and behavior change
Feider cited three reasons the company can lose prospective patients today. First, some patients prefer patch pumps; he said the leading patch pump competitor captures a large share of new starts and benefits from pharmacy reimbursement. Second, some patients prefer to actively manage pump settings rather than use an automated approach. Third, and most importantly in his view, the company is asking the industry to change established behavior, particularly within endocrinology practices built around traditional pump setup and management.
He said adoption of automation-forward pumping will take time because “doctors just don’t change behavior overnight.” As validation of the direction of travel, Feider noted that other pump companies are now discussing more automated, learning-based systems that incorporate weight-based inputs similar in concept to iLet.
Commercial expansion, Mint patch pump, and bi-hormonal development
On commercialization, Feider said Beta Bionics ended 2025 with 63 sales territories and is adding territories in 2026, with at least 20 new territories planned. He indicated most additions will be “front-loaded” into the first half of 2026. He estimated that roughly 120 to 180 territories could ultimately be appropriate for broad U.S. coverage across high-prescribing primary care and endocrinology, while noting he “reserve[s] the right to change [his] mind.”
Feider said the company does not need to expand the field sales force in order to grow adoption and does not view same-store productivity as capped. He added that new territories typically begin generating incremental revenue about a quarter after a representative is hired, while declining to provide more detailed ramp metrics.
Looking to the pipeline, Feider discussed “Mint,” the company’s planned patch pump, reiterating a commercialization target of “by the end of 2027.” He said Mint is intended to be similar to the incumbent patch pump in size, weight, capacity, waterproofing, and overall look. The key difference, he said, is a two-part design: a reusable component intended to last two years housing “expensive components,” and a disposable component replaced approximately every three days containing batteries, cannula, a syringe, and adhesive. He emphasized a simplified change-out process without phone pairing/unpairing and no recharging of the reusable component, since the batteries are in the disposable portion. Mint is expected to use the iLet algorithm.
Feider also addressed the company’s bi-hormonal concept, describing it as a “world-changing” approach that pairs insulin delivery with glucagon to reduce hypoglycemia risk and allow a more aggressive algorithm—“gas and brakes,” as he put it. He said the product could provide users more freedom from constantly thinking about glucose levels, while acknowledging trade-offs including incremental cost, larger device profile, and managing an additional drug. He said Beta Bionics holds exclusive rights to the glucagon drug and noted the company plans two phase II trials “this year,” followed by a phase III pivotal trial requiring at least a year of drug exposure, without providing a specific commercialization timeline.
Finally, Feider addressed a competitor’s “pay-as-you-go” announcement, characterizing it as aligned with a strategy Beta Bionics “pioneered” in the pharmacy channel. He said broader pharmacy reimbursement for insulin pumps would be positive for the industry, though he declined to comment on competitor-specific goals in detail.
About Beta Bionics (NASDAQ:BBNX)
Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.
At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.
Featured Stories
- Five stocks we like better than Beta Bionics
- Silver Is the New Oil—And the World’s Running Dry
- BNZI stands out as a Zacks Buy. Earnings momentum and analyst upgrades align
- What happened in Cyprus could be coming here
- Elon Musk’s $1 Quadrillion AI IPO
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
